News

LATEST UPDATES

READ MORE

New Funding Opportunity: Pancreatic Cancer Collective – Computational Approaches to Identifying High-Risk Pancreatic Cancer Populations

The Pancreatic Cancer Collective (PCC) invites applications for the Pancreatic Cancer Collective – Computational Approaches to Identifying High Risk Pancreatic Cancer Populations Grant. The Team(s) will develop tools to identify individuals in the general population who are at high risk for pancreatic cancer far earlier than they would otherwise be diagnosed, using information from existing dataset(s) (such as the OptumLabs Data Warehouse*, UK Biobank*, Danish National Patient Registry*, and/or other comparable datasets).

Read More
READ MORE

“I was the new Nobel Prize winner’s lab rat… Dr. James P. Allison won the Nobel Prize for his work with immunotherapy, which saved my life.” by SU2C-CRI Dream Team Advocate Mary Elizabeth Williams in SALON

Receiving the Nobel prize is an extraordinary lifetime achievement, but the impact of Dr. Jim Allison’s research can be life-changing for the patients who benefit, as shared in this personal account.

Read More
READ MORE

American Cancer Society Updates Colorectal Cancer Screening Guideline

The American Cancer Society (ACS) has released an updated guideline for colorectal cancer screening. Among the major guideline changes, the new recommendations say screening should begin at age 45 for people at average risk. Previously, the guideline recommended screening begin at age 50 for people at average risk. Recommendations for screening test options are also part of the guideline changes.

Please click here to learn more.

Read More
READ MORE

Nut Consumption May Aid Colon Cancer Survival

Charles S. Fuchs, MD, co-leader of the SU2C Colorectal Cancer Dream Team, is also head of a research that recently reported an intriguing finding: people with stage III colon cancer who regularly eat nuts are at significantly lower risk of cancer recurrence and mortality than those who don’t. The study followed 826 participants in a clinical trial for a median of 6.5 years after they were treated with surgery and chemotherapy. Those who regularly consumed at least two, one-ounce servings of nuts each week demonstrated a 42% improvement in disease-free survival and a 57% improvement in overall survival, according to a paper published in the Journal of Clinical Oncology. Earlier research among patients with colon cancer has indicated that patients are more likely to have poor outcomes when lifestyle factors such as obesity, high carbohydrate diet and lack of exercise increases their insulin resistance or raises blood sugar levels. “These studies support the hypothesis that behaviors that make you less insulin resistant, including eating nuts, seem to improve outcomes in colon cancer,” Fuchs said. “However, we don’t know yet what exactly about nuts is beneficial.” Nuts also might play a positive role by satisfying hunger with less intake of carbohydrates or other foods associated with poor outcomes, Fuchs noted. Dr. Fuchs is director of the Yale Cancer Center and physician-in-chief at the Smilow Cancer Hospital.

For more information, please click here.

Read More
READ MORE

SU2C-American Cancer Society Lung Cancer Dream Team Discover New Strategy in Treating Lung Cancer Patients

Dr. Janne and the SU2C-American Cancer Society Lung Cancer Dream Team have been focused on treating lung cancer patients with mutant KRAS. In this new publication, they report that a subgroup of patients with mutant KRAS may benefit from drugs called MEK inhibitors, if these patients do not have as much of the non-mutant KRAS protein. This information is helpful in deciding what treatments can be used for certain patients with mutant KRAS.

Read More
READ MORE

New Funding Opportunity: SU2C-CRUK Pediatric Brain Cancer Dream Team Translational Research Grant

Stand Up To Cancer (SU2C) and Cancer Research UK (CRUK) invite applications for the SU2C-CRUK Pediatric Brain Cancer Dream Team Translational Research Grant. The Dream Team will address critical problems in pediatric (age range up to 18 years) brain cancer treatment and positively impact patients in the near future. The project will accelerate the development of prevention strategies, diagnostic approaches or treatments for pediatric brain cancers through investigation by a collaborative multidisciplinary, multi-institutional, transatlantic Dream Team. The project must be designed to accelerate therapeutic application to the clinic with patient involvement within 4 years of the grant term. Additionally, the project can address issues around late stage effects of pediatric brain cancer treatment. Proposed ideas should be based on perceived opportunities for success as well as high-priority areas with a critical patient need.

For more information on how to apply, please click here.

Read More
READ MORE

New Funding Opportunity: Pancreatic Cancer Collective New Therapies Challenge

The Pancreatic Cancer Collective New Therapies Challenge represents a new, focused effort to increase the number of innovative and effective therapies to treat pancreatic cancer by support of pre-clinical and clinical development efforts. The Pancreatic Cancer Collective, a strategic collaboration of the Lustgarten Foundation and Stand Up To Cancer, will support collaborative, multi-disciplinary Teams to investigate novel or repurposed medicines, treatment strategies or technologies that have the potential to significantly impact pancreatic cancer patients in the near term.

For more information on how to apply, please click here.

Read More
READ MORE

Stand Up To Cancer T-Cell Lymphoma Dream Team Translational Research Grant

The Stand Up To Cancer T-Cell Lymphoma Dream Team Translational Research Grant will fund a translational cancer research project focused on T-cell lymphoma that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

For more information on how to apply, please click here.

Read More
READ MORE

Scientists Map Genomes of Brain Tumors in Search of Targets for Drug Treatment

Ependymomas are a type of brain tumor that is notoriously difficult to treat. Scientists with the SU2C-St. Baldrick’s Foundation Pediatric Cancer Dream Team mapped out the genetic landscape of selected ependymomas to find targets for treatment and reported encouraging preliminary data on the identification of drugs that could have an impact on the tumors. Their report, with Michael D. Taylor, MD, PhD, a principal investigator with the Dream Team, as a senior author, is published in Nature, the highest-ranked journal of general and multidisciplinary science in the world. Our colleagues at the American Association for Cancer Research have prepared the attached Science Update on the paper, discussing its importance in the quest to find treatments for these tumors that occur most often in infants and children. 

Read More
READ MORE

Emily Whitehead is Named One of the “10 People Who Mattered This Year” by Nature

Emily Whitehead, the little girl who was first person ever to receive the CAR-T treatment for leukemia, has been named one of the “ten people who mattered this year” by Nature, the world’s most influential journal of multidisciplinary science, marking FDA approval of the treatment, supported by SU2C research. “A young girl’s battle against leukemia inspired a new generation of cancer therapy,” Nature noted. Crystal Mackall, MD, co-leader of the SU2C-St. Baldrick’s Foundation Pediatric Cancer Dream Team, says the treatment is a “watershed.” Emily’s story is also told in this video from the 2014 SU2C telecast. 

Read More